|

SLS009 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: GFH009

Pipeline

Phase 1/2: 1

Top Sponsors

  • Sellas Life Sciences Group1

Indications

  • Hematologic Malignancies1
  • Cancer1

Birmingham, Alabama1 trial

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

O'Neal Comprehensive Cancer Center, University of Alabama

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.